newsfilter
← Latest News
Earnings Call Transcripts·

Zymeworks Portfolio Update - Zymeworks

ZYME

  • Financial Performance:

    • Generated nearly $1 billion in upfront payments and milestones to date from partnering activities.
    • Secured $55 million upfront payment and $40 million potential upon Phase 1b initiation for the Roche partnership (ZymeWorks will fund initial Phase 1a, Roche funds subsequent development).
    • Potential total deal value up to $718 million in milestones plus tiered royalties (high single-digits to mid-teens) extending into the 2040s.
    • R&D spending expected to decrease by approximately 20% compared to the prior year, aided by the Roche partnership shifting funding for ZW209.
    • Capital allocation includes continued share repurchase programs and potential M&A for strategic acquisitions or royalty opportunities.
    • ZymeWorks intends to maintain a diversified revenue model combining recurring cash flows from commercial products (Zahira, Upelry, Bybative) with licensing proceeds.

  • Guidance and Future Outlook:

    • ZW209 (DLL3 Tri-TCE) first patient dose expected in 2026, immediately following HSR clearance; Phase 1b initiation anticipated after Phase 1a results.
    • ZW191 (FRα ADC) will continue to mature; strategic options including partnering for registration are being evaluated with MTS, with no plans to fund Phase 3 independently due to market competition.
    • A new R&D day is scheduled for Q1 2027, with visibility on preclinical programs expected before year-end 2026.
    • No quarterly earnings call scheduled for Q3; full-year financial results and investor calls planned for late February/early March 2027.
    • Long-term goal is to build a durable, diversified business with multiple pathways for value creation through innovation, partnerships, and selective business development.

  • Business Segments and Product Lines:

    • ZW209 (Roche Partnership): Asymmetric COSTIM tri-specific T-cell engager targeting DLL3; designed for conditional CD28 co-stimulation only upon CD3 binding to limit toxicity. Roche assumes responsibility for development and commercialization post-Phase 1a.
    • ZW191 (Ovarian Cancer ADC): Folate Receptor Alpha antibody-drug conjugate; demonstrated 65% ORR at 6.4 mg/kg and 55% ORR at 9.6 mg/kg in platinum-resistant ovarian cancer (high-grade serous).
    • Zahira/Xanidazimab (Partnered with Janssen/Biogen): Horizon GEA01 data (ESMO) showed median OS of 27 months for first-line HER2+ GEAs (triplet regimen), cementing the backbone therapy status.
    • ZW251 (GPC3 Program): Ongoing study in hepatocellular carcinoma (HCC); data maturity timeline to be determined as competition intensifies.
    • Pan-RAS Program: Advanced preclinical/early development; targeting partnership via spin-out, carve-out, or co-creation.

  • Market and Competitive Landscape:

    • Ovarian Cancer: Highly competitive ADC landscape with moves toward earlier lines and combination regimens; ZW191 aims to differentiate via efficacy and safety profile.
    • SCLC/DLL3: Competitive environment with Tarlatamab (Biogen); ZW209 targets improvement in durability and response depth via costimulation mechanism.
    • HER2+ GEAs: Zahira established as a standard of care in first-line setting, outperforming trastuzumab-based regimens in survival data.
    • Platform Advantage: ZymeWorks' proprietary asymmetric platform and AI-guided engineering allow for rapid iteration and differentiation across multiple tumor types (solid tumors and hematologic malignancies).

  • Risks and Challenges:

    • Regulatory: Roche partnership contingent upon successful HSR (antitrust) clearance.
    • Clinical: Solid tumor T-cell engagers face challenges with tumor microenvironment resistance and antigen loss; ZW209 addresses this via conditional co-stimulation but requires clinical validation.
    • Commercial: ZW191 requires a partner to fund expensive Phase 3 trials and manage combination regimens against established competitors.
    • Development: Potential for antigen loss (DLL3 downregulation) remains a resistance mechanism; ZymeWorks posits costimulation may mitigate this but clinical proof is needed.
    • Capital: Dependence on successful partnering to replenish the pipeline without over-burdening the balance sheet.

  • Management Commentary and Tone:

    • Tone was confident and strategic, emphasizing a "capital-efficient" partnering model over self-funding all programs.
    • Management highlighted the "repeatable" nature of their R&D lifecycle: originate science, identify partners, share risk, retain royalties/milestones.
    • Expressed strong belief in the differentiated design of ZW209 and the efficacy of ZW191, despite the competitive landscape.
    • Clear stance on capital allocation: prioritizing partnerships for assets requiring significant downstream investment (ZW191, ZW209) while retaining internal R&D for novel science and platform expansion.

  • Analyst Questions and Answers:

    • Partnering ZW191: Management confirmed ZW191 will be actively partnered (via MTS) rather than self-funded for Phase 3 due to competition and capital requirements; unlikely to move forward without a partner.
    • ZW209 Clinical Signals: Differentiation will be assessed in Phase 1b via response rates, tolerability, and combination potential; early Phase 1a data focuses on safety and mechanism.
    • Dose Selection for ZW191: 6.4 mg/kg selected due to favorable safety/efficacy balance; higher dose (9.6 mg/kg) showed comparable efficacy with more toxicity; further dosing depends on partner interest and combination data.
    • ZW209 Mechanism: Costimulation via CD28 is conditional on CD3 binding, reducing fractricide risk; designed to improve T-cell fitness and durability compared to bispecifics like Tarlatamab.
    • ZW251 Data Timing: No specific timeline provided for GPC3 data; waiting for appropriate maturity to tell the complete story in a competitive HCC space.
    • Zahira Category 1 Upgrade: Management deferred to Janssen for guidance on labeling upgrades and 2027 uptake expectations.

  • Other Key Points:

    • No geographic differences in efficacy or safety observed for ZW191 between Asian and Western patients (though study size was limited).
    • ZW209 Phase 1a will be conducted by ZymeWorks, allowing Roche to shape early development while avoiding time loss; Roche assumes subsequent development and commercialization.
    • Management plans to explore "R&D spin-offs" or dedicated vehicles for future partnerships to further optimize capital allocation.
    • Horizon GEA01 data showed sustained survival at 3-year follow-up with the triplet regimen, reinforcing Zahira's position in the HER2+ GEAs market.